Meet Our Advisory Board
Bill Moffitt
Board Chair
William Moffitt is an accomplished chief executive and board chairman with a proven track
record of leading corporations --- of all market capitalizations, public and private --- in the rapid
development of cutting-edge technologies and the commercialization of products and solutions
that have helped shape the healthcare industry. From innovative, high-tech start-ups to larger
more mature companies, Mr. Moffitt possesses demonstrated ability to attract and maintain Wall
Street support at all stages of a company’s development.
Until his retirement in early 2013, Mr. Moffitt was President, Chief Executive Officer and a
director of Nanosphere, a developer, manufacturer and marketer of an advanced molecular
diagnostic platform for the early detection of disease. Under his leadership Nanosphere
transformed itself from a development stage company to a publicly listed commercialization
company with a pipeline of products to drive continued growth and profitability.
Prior to his tenure at Nanosphere, he was President, Chief Executive Officer and a director of i-
STAT Corporation, a developer, manufacturer and marketer of diagnostic products that
pioneered the point-of-care blood analysis market. Moffitt led i-STAT from its early research
stage to commercialization and through its initial public offering to its premium acquisition by
Abbott Laboratories in 2003.
Prior to i-STAT Moffitt held executive positions at Baxter Healthcare Corporation, a
manufacturer and distributor of health care products, and American Hospital Supply
Corporation, a diversified manufacturer and distributor of health care products, which Baxter
acquired in 1985.
Moffitt has been a director and chairman of numerous private and public medical technology
companies, commencing in the development stage progressing through to successful exits for
many. Currently, Moffitt serves as chairman of Altoida, chairman of First Light Bioscience and
chairman of Momentum BioScience, Ltd.
Moffitt earned a B.S. from Duke University.
Ioannis Tarnanas, Ph.D.
Co-founder
Ioannis is a co-founder and Chief Scientific Officer at Altoida. Ioannis’ research focuses on using new technologies to understand the aging process and to establish prevention methods that decrease the risk of developing dementia or delay the onset of the disease. Ioannis has developed models and screens of dementia using computerized tests of complex, real-life activities, such as a novel assessment of spatial navigation and movement trajectory. With this technology, Ioannis is developing a predictive tool based on cognitive and non-cognitive biomarkers of early onset dementia.
At Altoida, Ioannis will pursue his development of computational biomarkers of Alzheimer’s disease. He is also working with local and international Alzheimer advocacy organizations to develop a responsible strategy to implement this technology and enable machine intelligence for disease prevention
Discover Your Path to Better Brain Health
At Altoida, we provide digital biomarker technology that allows you to understand your brain health early to take the right next steps. Connect with our team today.